Q3 Earnings Forecast for Novavax Issued By Zacks Research

Novavax, Inc. (NASDAQ:NVAX) – Equities researchers at Zacks Research issued their Q3 2027 earnings per share (EPS) estimates for shares of Novavax in a report released on Thursday, March 19th. Zacks Research analyst Team expects that the biopharmaceutical company will post earnings per share of ($0.01) for the quarter. The consensus estimate for Novavax’s current full-year earnings is ($1.46) per share. Zacks Research also issued estimates for Novavax’s Q4 2027 earnings at $0.08 EPS.

Novavax (NASDAQ:NVAX) last posted its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported $0.11 earnings per share for the quarter, beating the consensus estimate of ($0.66) by $0.77. The business had revenue of $136.40 million for the quarter, compared to the consensus estimate of $90.26 million. Novavax had a negative return on equity of 673.17% and a net margin of 39.19%.The company’s quarterly revenue was up 66.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.51) EPS.

NVAX has been the topic of several other research reports. HC Wainwright increased their price target on shares of Novavax from $11.00 to $16.00 and gave the stock a “buy” rating in a report on Friday, February 27th. Jefferies Financial Group restated a “buy” rating on shares of Novavax in a research note on Thursday, March 12th. Weiss Ratings upgraded shares of Novavax from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, March 12th. Wall Street Zen raised shares of Novavax from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Finally, BTIG Research restated a “buy” rating and set a $19.00 target price on shares of Novavax in a research report on Tuesday, January 20th. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Novavax has an average rating of “Hold” and a consensus target price of $11.88.

Novavax Trading Down 4.7%

Novavax stock opened at $9.26 on Monday. The stock has a 50-day moving average price of $9.32 and a 200 day moving average price of $8.26. The company has a market capitalization of $1.51 billion, a price-to-earnings ratio of 3.84 and a beta of 2.54. Novavax has a 52 week low of $5.01 and a 52 week high of $11.97. The company has a quick ratio of 2.10, a current ratio of 2.13 and a debt-to-equity ratio of 5.93.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Flagship Harbor Advisors LLC acquired a new stake in shares of Novavax during the 4th quarter worth approximately $33,000. Quarry LP acquired a new position in shares of Novavax in the 3rd quarter valued at $33,000. State of Wyoming acquired a new position in shares of Novavax in the 2nd quarter valued at $52,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Novavax by 25.8% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,896 shares of the biopharmaceutical company’s stock worth $53,000 after buying an additional 1,617 shares in the last quarter. Finally, Danske Bank A S acquired a new stake in Novavax during the third quarter valued at $64,000. 53.04% of the stock is owned by institutional investors and hedge funds.

Novavax News Summary

Here are the key news stories impacting Novavax this week:

• Positive Sentiment: Quarterly results showed an upside: Novavax reported $0.11 EPS and $136.4M revenue (both ahead of consensus), and revenue grew ~66.6% year‑over‑year — a near‑term positive for sentiment.
• Positive Sentiment: Analysts and commentaries note potential upside from licensing income and renewed COVID vaccine demand that could support future revenue and valuation recovery. Assessing Novavax (NVAX) Valuation As Licensing Income And COVID Momentum Shape Expectations
• Neutral Sentiment: Sector pieces and stock‑selection articles mention healthcare/therapeutics themes that can drive episodic interest but don’t provide firm directional catalysts specific to Novavax. Therapeutics Stocks Q4 In Review: United Therapeutics (NASDAQ:UTHR) Vs Peers These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
• Neutral Sentiment: Short‑interest reports released today contain inconsistent/zero values (0 shares, NaN increases, 0.0 days ratio) — the conflicting data can create uncertainty and short‑term volatility rather than a clear directional signal.
• Negative Sentiment: Balance‑sheet and forward outlook remain concerns: the company shows high leverage (debt/equity ~5.93) and analysts still model negative full‑year EPS, which can limit investor enthusiasm despite the recent beat.
• Negative Sentiment: Technical/flow factors: intraday weakness vs. the 50‑day average, lighter trading volume versus some recent periods and profit‑taking after recent gains are consistent with the price decline observed.

About Novavax

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.